Mountain View, CA, United States of America

Karen Lariosa-Willingham

USPTO Granted Patents = 2 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015-2017

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Karen Lariosa-Willingham

Introduction

Karen Lariosa-Willingham is an accomplished inventor based in Mountain View, California. She has made significant contributions to the field of biotechnology, particularly in the development of compounds that modulate cell proliferation, differentiation, and survival. With two patents to her name, her work has the potential to impact various medical treatments.

Latest Patents

Karen's latest patents include "Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival." This invention discloses erythropoietin-mimetic compounds that modulate the survival, function, or differentiation of kidney cells, neurons, erythroid cells, and other erythropoietin-responsive cells. The compounds are useful in preventing and treating diseases such as anemia, organ injury, and diseases of the central nervous system. They also serve as adjuncts to cellular treatments, including stem cell therapies.

Career Highlights

Karen Lariosa-Willingham is currently employed at Stategics, Inc., where she continues to innovate and develop new therapeutic solutions. Her expertise in biotechnology and her dedication to research have positioned her as a key player in her field.

Collaborations

Throughout her career, Karen has collaborated with notable colleagues, including Juha Punnonen and Jeffrey R Spencer. These partnerships have enhanced her research and contributed to the advancement of her inventions.

Conclusion

Karen Lariosa-Willingham's work exemplifies the impact of innovative thinking in biotechnology. Her patents reflect her commitment to improving health outcomes through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…